Compugen Ltd. announced on November 5, 2024, that data supporting the anti-tumor activity and safety profile of its triple combination therapy, COM701, COM902, and pembrolizumab, in advanced heavily pre-treated patients with platinum resistant ovarian cancer (PROC) was published as an abstract for the Society for Immunotherapy of Cancer (SITC) 2024 Annual Meeting.
The study, involving 23 efficacy-evaluable patients, demonstrated a confirmed objective response rate (ORR) of 17.4%, including one complete response (CR) and three partial responses (PR). The confirmed disease control rate (DCR) was 43.5%, with the majority of adverse events (AEs) being Grade 2 or less, indicating a favorable safety profile.
These results, consistent with previously presented data, support the unique mechanism of action of COM701 and its potential clinical benefit in ovarian cancer patients. The company is encouraged by feedback from ovarian cancer experts to advance COM701 to an earlier setting of ovarian cancer therapy, specifically in platinum-sensitive ovarian cancer patients who lack additional maintenance treatment options.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.